I think it's interesting that the ACR scores are higher across the board for the monotherapy treatment arm compared to the combination-therapy arm, which incorporated methotrexate. However, the DAS28 scores are much higher in the combination-therapy arm.
RIGL has only tested R788 in combination therapy with methotrexate so I think it's only reasonable to compare those arms when comparing the efficacy data between R788 and PFE's oral JAK inhibitor. Based on this data and similar data from RIGL's 24-week Phase 2b trial of R788, the efficacy between the compounds appears to be about a dead heat. Here is R788's data: http://ir.rigel.com/phoenix.zhtml?c=120936&p=irol-newsArticle&ID=1305912&highlight=
In particular, the main dose of R788 being carried forward (100mg bid) demonstrated ACR 20/50/70 and DAS28 scores of 66%, 43%, 28%, and 27%, respectively. Again, it looks to be pretty much a deat heat as far as efficacy goes between R788 and the best scores (not sure which dose PFE is carrying forward) from PFE's JAK inhibitor which occurred at the 15 mg dose (59%, 44%, 31%, and 30%, respectively).
Market Data 
Markets 
AI
